IceCure Medical Ltd. (NASDAQ: ICCM) reported a 70% increase in its U.S. active commercial install base of its ProSense® cryoablation system for breast cancer since receiving FDA marketing authorization in October 2025, according to a company statement.

The Israel-based medical device company said ProSense® procedures have been performed in multiple major U.S. cities, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, and Memphis.

IceCure also reported a rise in sales leads generated at two medical conferences held earlier this year — the Society of Breast Imaging Annual Symposium and the American Society of Breast Surgeons Annual Meeting — compared to the same events in 2025, prior to FDA authorization.

The American Society of Breast Surgeons recently updated its Resource Guide to recommend cryoablation as a local treatment option for low-risk breast cancer patients, which IceCure cited as a factor supporting adoption.

The ProSense® system is described by the company as the first device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgery.

"With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S.," said Eyal Shamir, IceCure's chief executive officer.

The company also noted media coverage of the ProSense® system, including segments aired across approximately 190 CBS and CW-affiliated television stations nationwide.

IceCure develops liquid-nitrogen-based cryoablation systems for the destruction of benign and cancerous tumors, with focus areas including breast, kidney, bone, and lung cancer. The company markets its products in the U.S., Europe, and Asia.